|
1) Canellos GP, Niedzwiecki D. Long-term follow-up of Hodgkinʼs disease trial. N Engl J Med. 2002; 346: 1417-8
|
|
|
|
2) Duggan DB, Petroni GR, Johnson JL, et al. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkinʼs disease: report of an intergroup trial. J Clin Oncol. 2003; 21: 607-14
|
|
|
|
|
|
3) Brusamolino E, Bacigalupo A, Barosi G, et al. Classical Hodgkinʼs lymphoma in adults: guidelines of the Italian Society of Hematology, the Italian Society of Experimental Hematology, and the Italian Group for Bone Marrow Transplantation on initial work-up, management, and follow-up. Haematologica. 2009; 94: 550-65
|
|
|
|
|
|
4) Noordijk EM, Carde P, Dupouy N, et al. Combined-modality therapy for clinical stage I or II Hodgkinʼs lymphoma: long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials. J Clin Oncol. 2006; 24: 3128-35
|
|
|
|
|
|
5) Fermé C, Eghbali H, Meerwaldt JH, et al. EORTC-GELA H8 Trial. Chemotherapy plus involved-field radiation in early-stage Hodgkinʼs disease. N Engl J Med. 2007; 357: 1916-27
|
|
|
|
|
|
6) Engert A, Franklin J, Eich HT, et al. Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkinʼs lymphoma: final results of the GHSG HD7 trial. J Clin Oncol. 2007; 25: 3495-502
|
|
|
|
|
|
7) Aleman BM, Re D, Diehl V. The role of radiation therapy in patients with Hodgkinʼs lymphoma. Curr Hematol Malig Rep. 2007; 2: 151-60
|
|
|
|
|
|
8) Viviani S, Bonadonna G, Santoro A, et al. Alternating versus hybrid MOPP and ABVD combinations in advanced Hodgkinʼs disease: ten-year results. J Clin Oncol. 1996; 14: 1421-30
|
|
|
|
|
|
9) Connors JM, Klimo P, Adams G, et al. Treatment of advanced Hodgkinʼs disease with chemotherapy-comparison of MOPP/ABV hybrid regimen with alternating courses of MOPP and ABVD: a report from the National Cancer Institute of Canada clinical trials group. J Clin Oncol. 1997; 15: 1638-45
|
|
|
|
|
|
10) Federico M, Luminari S, Iannitto E, et al. HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkinʼs lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. J Clin Oncol. 2009; 27: 805-11
|
|
|
|
|
|
11) Klimm B, Eich HT, Haverkamp H, et al. German Hodgkin Study Group. Poorer outcome of elderly patients treated with extended-field radiotherapy compared with involved-field radiotherapy after chemotherapy for Hodgkinʼs lymphoma: an analysis from the German Hodgkin Study Group. Ann Oncol. 2007; 18: 357-63
|
|
|
|
|
|
12) Landgren O, Algernon C, Axdorph U, et al. Hodgkinʼs lymphoma in the elderly with special reference to type and intensity of chemotherapy in relation to prognosis. Haematologica. 2003; 88: 438-44
|
|
|
|
|
|
13) Ballova V, Rüffer JU, Haverkamp H, et al. A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkinʼs disease comparing BEACOPP baseline and COPP-ABVD (study HD9 elderly). Ann Oncol. 2005; 16: 124-31
|
|
|
|
|
|
14) Hutchings M, Loft A, Hansen M, et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood. 2006; 107: 52-9
|
|
|
|
|
|
15) Gallamini A, Hutchings M, Rigacci L, et al. Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkinʼs lymphoma: a report from a joint Italian-Danish study. J Clin Oncol. 2007; 25: 3746-52
|
|
|
|
|
|
16) Buglio D, Georgakis G, Younes A. Novel small-molecule therapy of Hodgkin lymphoma. Expert Rev Anticancer Ther. 2007; 7: 735-40
|
|
|
|
|
|
17) Küppers R. The biology of Hodgkinʼs lymphoma. Nat Rev Cancer. 2009; 9: 15-27
|
|
|
|
|
|
18) Clodi K, Younes A. Reed-Sternberg cells and the TNF family of receptors/ligands. Leuk Lymphoma. 1997; 27 (3-4): 195-205
|
|
|
|
|
|
19) Fiumara P, Snell V, Li Y, et al. Functional expression of receptor activator of nuclear factor- kappa B in Hodgkin disease cell lines. Blood. 2001; 98: 2784-90
|
|
|
|
|
|
20) Younes A, Garg A, Aggarwal BB. Nuclear transcription factor-kappa B in Hodgkinʼs disease. Leuk Lymphoma. 2003; 44: 929-35
|
|
|
|
|
|
21) Zheng B, Fiumara P, Li YV, et al. MEK/ERK pathway is aberrantly active in Hodgkin disease: a signaling pathway shared by CD30, CD40, and RANK that regulates cell proliferation and survival. Blood. 2003; 102: 1019-27
|
|
|
|
|
|
22) Younes A, Aggarwall BB. Clinical implications of the tumor necrosis factor family in benign and malignant hematologic disorders. Cancer. 2003; 98: 458-67
|
|
|
|
|
|
23) Giacomelli R, Cipriani P, Lattanzio R, et al. Circulating levels of soluble CD30 are increased in patients with systemic sclerosis (SSc) and correlate with serological and clinical features of the disease. Clin Exp Immunol. 1997; 108: 42-6
|
|
|
|
|
|
24) Bartlett NL, Younes A, Carabasi MH, et al. A phase 1 multidose study of SGN-30 immuno-therapy in patients with refractory or recurrent CD30＋ hematologic malignancies. Blood. 2008; 111: 1848-54
|
|
|
|
|
|
25) Ansell SM, Horwitz SM, Engert A, et al. Phase I/II study of an anti-CD30 monoclonal antibody(MDX-060)in Hodgkinʼs lymphoma and anaplastic large-cell lymphoma. J Clin Oncol. 2007; 25: 2764-9
|
|
|
|
|
|
26) Lawrence CE, Hammond PW, Zalevsky J, et al. XmAbTM2513, an Fc engineered humanized anti-CD30 monoclonal antibody, has potent in vitro and in vivo activities, and has the potential for treating hematologic malignancies. Blood. 2007; 110: 2340
|
|
|
|
|
|
27) Younes A, Zalevsky J, Blum KA, et al. Evaluation of the pharmacokinetics, immunogenicity, and safety of XmAb®2513 in the ongoing study XmAb2513-01: a phase 1 study of every other week XmAb2513 to evaluate the safety, tolerability, and pharmacokinetics in patients with Hodgkin lymphoma or anaplastic large cell lymphoma. Blood. 2008; 112: 5012
|
|
|
|
|
|
28) Oflazoglu E, Kissler KM, Sievers EL, et al. Combination of the anti-CD30-auristatin-E antibody-drug conjugate(SGN-35)with chemotherapy improves antitumour activity in Hodgkin lymphoma. Br J Haematol. 2008; 142: 69-73
|
|
|
|
|
|
29) Younes A, Forero-Torres A, Bartlett NL, et al. Multiple complete responses in a phase 1 dose-escalation study of the antibody-drug conjugate SGN-35 in patients with relapsed or refractory CD30-positive lymphomas. Blood. 2008; 112: 1006
|
|
|
|
|
|
30) Barlett N, Forero-Torres A, Rosenblatt J, et al. Complete remissions with weekly dosing of SGN-35, a novel antibody-drug conjugate (ADC) targeting CD30, in a phase 1 dose-escalation study in patients with relapsed or refractory Hodgkin lymphoma or systemic anaplastic large cell lymphoma. Proc ASCO. 2009; 27: 8500
|
|
|
|
|
|
31) Glozak MA, Seto E. Histone deacetylases and cancer. Oncogene. 2007; 26: 5420-32
|
|
|
|
|
|
32) Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov. 2006; 5: 769-84
|
|
|
|
|
|
33) Buglio D, Georgakis GV, Hanabuchi S, et al. Vorinostat inhibits STAT6-mediated TH2 cytokine and TARC production and induces cell death in Hodgkin lymphoma cell lines. Blood. 2008; 112: 1424-33
|
|
|
|
|
|
34) Younes A, Wedwood A, McLaughlin P, et al. Treatment of relapsed or refractory lymphoma with oral isotype-selective histone deacetylase inhibitor MGCD0103: interim results from a phase 2 study. Blood. 2007; 110: 2571
|
|
|
|
|
|
35) Dickinson M, Ritchie D, DeAngelo DJ, et al. Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin lymphoma. Br J Haematol. 2009; 147: 97-101
|
|
|
|
|
|
36) Kirschbaum MH, Goldman BH, Zain JM, et al. Vorinostat in relapsed or refractory Hodgkin lymphoma: SWOG0517. Blood. 2007; 110: 2574
|
|
|
|
|
|
37) Fehniger TA, Larson S, Trinkaus K, et al. A phase 2 multicenter study of lenalidomide in patients with relapsed or refractory classical Hodgkin lymphoma: preliminary results. Blood. 2008; 112: 2595
|
|
|
|
|
|
38) Kuruvilla J, Taylor D, Wang L, et al. Phase 2 trial of lenalidomide in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2008; 112: 3052
|
|
|
|
|
|
39) Jones RJ, Gocke CD, Kasamon YL, et al. Circulating clonotypic B cells in classic Hodgkin lymphoma. Blood. 2009; 113: 5920-6
|
|
|
|
|
|
40) Younes A, Romaguera J, Hagemeister F, et al. A pilot study of rituximab in patients with recurrent, classic Hodgkin disease. Cancer. 2003; 98: 310-4
|
|
|
|
|
|
41) Wedgwood AR, Pro B, Younes A. The lymphomas: molecular pathways and novel therapeutic targets. Curr Hematol Rep. 2005; 4: 324-34
|
|
|
|
|
|
42) Bollard CM, Huls MH, Buza E, et al. Administration of latent membrane protein 2-specific cytotoxic T lymphocytes to patients with relapsed Epstein-Barr virus-positive lymphoma. Clin Lymphoma Myeloma. 2006; 6: 342-7
|
|
|
|
|